CAPP-Seq ctDNA profiling was employed to study resistance mechanisms in 43 patients with advanced NSCLC who were treated with rociletinib, a third-generation EGFR TKI [75]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.